Nothing Special   »   [go: up one dir, main page]

DK0736303T3 - Interferonopløsning - Google Patents

Interferonopløsning

Info

Publication number
DK0736303T3
DK0736303T3 DK96105142T DK96105142T DK0736303T3 DK 0736303 T3 DK0736303 T3 DK 0736303T3 DK 96105142 T DK96105142 T DK 96105142T DK 96105142 T DK96105142 T DK 96105142T DK 0736303 T3 DK0736303 T3 DK 0736303T3
Authority
DK
Denmark
Prior art keywords
interferon
Prior art date
Application number
DK96105142T
Other languages
English (en)
Inventor
Guenter Gross
Sabino Del Terzo
Saran Kandakuri Kumar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0736303T3 publication Critical patent/DK0736303T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
DK96105142T 1995-04-06 1996-03-30 Interferonopløsning DK0736303T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
DK0736303T3 true DK0736303T3 (da) 2000-01-10

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96105142T DK0736303T3 (da) 1995-04-06 1996-03-30 Interferonopløsning

Country Status (32)

Country Link
US (1) US5762923A (da)
EP (1) EP0736303B1 (da)
JP (1) JP2758154B2 (da)
KR (1) KR100212346B1 (da)
CN (1) CN1066065C (da)
AR (1) AR002932A1 (da)
AT (1) ATE183650T1 (da)
AU (1) AU685356B2 (da)
BR (1) BR9601276A (da)
CA (1) CA2172664C (da)
CO (1) CO4750807A1 (da)
CY (1) CY2194B1 (da)
CZ (1) CZ287626B6 (da)
DE (1) DE69603894T2 (da)
DK (1) DK0736303T3 (da)
ES (1) ES2136910T3 (da)
GR (1) GR3031775T3 (da)
HK (1) HK1012232A1 (da)
HU (1) HU227643B1 (da)
IL (1) IL117752A (da)
MA (1) MA23838A1 (da)
MY (1) MY113594A (da)
NO (1) NO316801B1 (da)
NZ (1) NZ286300A (da)
PE (1) PE38897A1 (da)
PL (1) PL183873B1 (da)
RU (1) RU2113845C1 (da)
SA (1) SA96160728B1 (da)
SG (1) SG52806A1 (da)
TR (1) TR199600287A2 (da)
TW (1) TW426523B (da)
ZA (1) ZA962553B (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ATE297761T1 (de) * 1998-03-26 2005-07-15 Schering Corp Zubereitungen zur stabilisierung von peg- interferon alpha konjugaten
PT1069912E (pt) * 1998-04-03 2007-09-14 Novartis Vaccines & Diagnostic Formulações injectáveis de igf contendo succinato como agente tampão
CA2331823A1 (en) 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
BR9911076A (pt) * 1998-06-08 2001-02-20 Hoffmann La Roche Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
NZ508874A (en) * 1998-07-23 2004-03-26 Lilly Co Eli FSH and FSH variant formulations, products and methods of treating infertility.
ES2649840T3 (es) 1998-08-06 2018-01-15 Mountain View Pharmaceuticals, Inc. Uricasa tetramérica aislada
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6685931B1 (en) * 1998-12-22 2004-02-03 Schering Corporation Treatment of hepatitis C virus infections with interleukin-10
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ES2319776T3 (es) 1999-04-08 2009-05-12 Schering Corporation Terapia de melanoma.
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6994847B2 (en) 2000-11-07 2006-02-07 Chiron Corporation Stabilized interferon compositions
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
CN100411683C (zh) 2002-05-21 2008-08-20 阿斯比奥制药株式会社 含有生长素释放肽的药物组合物
JP4699991B2 (ja) 2003-04-02 2011-06-15 アレス トレーディング ソシエテ アノニム 非イオン性界面活性剤を一緒に伴うｆｓｈ及びｌｈの液体医薬組成物
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
AU2004248931B2 (en) 2003-06-20 2009-07-16 Ares Trading S.A. Freeze-dried FSH / LH formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
EA012205B1 (ru) 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
ZA200610041B (en) * 2004-06-01 2008-07-30 Ares Trading Sa Method of stabilizing proteins
DE602005022895D1 (de) 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
EP1800689B1 (en) 2004-08-24 2016-12-28 Daiichi Sankyo Company, Limited Liquid preparation of physiologically active peptide
SI3321359T1 (sl) 2005-04-11 2021-07-30 Horizon Pharma Rheumatology Llc Variantne oblike urat oksidaze in uporaba le-teh
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
EP1916997B1 (en) * 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Pharmaceutical compositions of bupropion
NZ578065A (en) 2007-01-16 2012-09-28 Abbott Lab Methods for treating psoriasis with an antibody which binds to an epitope
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
KR101502645B1 (ko) * 2007-09-04 2015-03-13 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ｂ, 이의 제조 방법 및 용도
EP2196475B1 (en) * 2007-09-04 2012-06-06 Biosteed Gene Expression Tech. CO., LTD. INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
DK2234645T3 (da) 2007-12-20 2012-07-09 Merck Serono Sa Peg-interferon-beta-formuleringer
WO2009150284A2 (es) 2008-06-13 2009-12-17 Proyecto De Biomedicina Cima, S.L. Conjugados de apo-a para la administración de compuestos biológicamente activos
WO2010033226A1 (en) * 2008-09-17 2010-03-25 Nektar Therapeutics Oligomer-protease inhibitor conjugates
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CN107073080A (zh) * 2014-09-23 2017-08-18 豪夫迈·罗氏有限公司 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
EP0396777A4 (en) * 1988-11-14 1991-03-13 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon

Also Published As

Publication number Publication date
ZA962553B (en) 1996-10-07
CN1066065C (zh) 2001-05-23
JP2758154B2 (ja) 1998-05-28
IL117752A (en) 2000-11-21
NO316801B1 (no) 2004-05-18
PE38897A1 (es) 1997-10-04
EP0736303A2 (en) 1996-10-09
NO961322L (no) 1996-10-07
AR002932A1 (es) 1998-05-27
AU5044696A (en) 1996-10-17
CA2172664A1 (en) 1996-10-07
SG52806A1 (en) 1998-09-28
EP0736303B1 (en) 1999-08-25
CZ287626B6 (en) 2001-01-17
CZ99496A3 (en) 1996-10-16
KR960037063A (ko) 1996-11-19
TW426523B (en) 2001-03-21
HUP9600857A3 (en) 1998-01-28
EP0736303A3 (en) 1997-02-26
HK1012232A1 (en) 1999-07-30
US5762923A (en) 1998-06-09
MA23838A1 (fr) 1996-12-31
GR3031775T3 (en) 2000-02-29
TR199600287A2 (tr) 1997-03-21
SA96160728B1 (ar) 2005-05-04
HU9600857D0 (en) 1996-05-28
CN1141808A (zh) 1997-02-05
DE69603894D1 (de) 1999-09-30
IL117752A0 (en) 1996-08-04
KR100212346B1 (ko) 1999-08-02
HU227643B1 (en) 2011-10-28
DE69603894T2 (de) 2000-04-20
JPH08283176A (ja) 1996-10-29
ES2136910T3 (es) 1999-12-01
BR9601276A (pt) 1998-01-13
PL183873B1 (pl) 2002-07-31
CA2172664C (en) 2000-10-03
RU2113845C1 (ru) 1998-06-27
CY2194B1 (en) 2002-11-08
NO961322D0 (no) 1996-04-01
NZ286300A (en) 1997-05-26
HUP9600857A2 (en) 1997-08-28
AU685356B2 (en) 1998-01-15
ATE183650T1 (de) 1999-09-15
MY113594A (en) 2002-04-30
CO4750807A1 (es) 1999-03-31
PL313655A1 (en) 1996-10-14

Similar Documents

Publication Publication Date Title
DK0736303T3 (da) Interferonopløsning
DK0809996T3 (da) Interferonkonjugater
DE59602881D1 (de) Sollwertgeber
NO976058L (no) Rekombinant mistellectin
ATA135896A (de) Skibob
ATE198470T1 (de) Alkenyl-benzoylguanidine
ATE240972T1 (de) Cyclopeptolide
ATA119896A (de) Scheibenmähwerk
BR9501643A (pt) Helistato
KR960038266U (ko) 개량 권척
KR970028193U (ko) 개량신문
BR7500040U (pt) Raquet mastit
BR7500192U (pt) Parasitofiltro
BR7500437U (pt) Girolight
BR7500703U (pt) Rodopratic
BR7500809U (pt) Tele-negocios
BR7500825U (pt) Chutegol
BR7500838U (pt) Vassourágua
BR7500991U (pt) Caríndio
BR7501298U (pt) Torre-audio-visual
BR7501299U (pt) Geladeira-prática
BR7501301U (pt) Guarda-chuva-mochila
BR7501303U (pt) Dupla-embalagem
BR7501376U (pt) Massarreal
BR7501399U (pt) Ciclonavegador